I remember in one of their calls a while back Retrophin refused to state how many patients in the Ph3 were staying on the upper dose (the study lets them step down) which doesnt sound massively encouraging for them in terms of the edema rates
I had a conversation with their CEO about a year ago and he couldn't give a straight answer about the decision to continue the higher of the two doses to Ph3, when they had just given a presentation highlighting the safety of the lower dose in Ph2.
I'm not sure sparsentan will be a magic bullet in fsgs by any stretch of the imagination
Oct 2, page-47
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.020(4.94%) |
Mkt cap ! $234.0M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 43.3¢ | 42.0¢ | $542.9K | 1.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5026 | 42.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 2827 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |